Workflow
Earnings beat
icon
Search documents
Is CVNA Stock a Buy Pre-Q1 Earnings? Key Metrics to Watch
ZACKS· 2025-05-05 13:51
Core Viewpoint - Carvana is expected to report first-quarter 2025 results with earnings estimated at 75 cents per share and revenues at $4.04 billion, reflecting a year-over-year revenue increase of 32% [1][2]. Financial Performance - The earnings estimate for Q1 2025 has increased by 2 cents over the past week, compared to a loss of 41 cents per share in the same quarter last year [2]. - The Zacks Consensus Estimate for 2025 revenues is projected at $17.20 billion, indicating a 25.8% year-over-year rise, while the EPS estimate is $3.67, suggesting a significant increase of 130.8% [4]. Sales and Growth - Carvana's used vehicle retail sales have returned to growth in Q1 2024, selling over 100,000 vehicles in each of the last three quarters of 2024, with a 50% year-over-year surge in retail units sold in Q4 2024 [6]. - The company anticipates a 32.6% year-over-year increase in retail units sold for Q1 2025, reaching approximately 121,868 vehicles [6]. Operational Efficiency - Carvana's adjusted EBITDA is estimated to rise by 85% year-over-year to $434.5 million for Q1 2025, driven by improved operational efficiency and cost-cutting measures [7]. - The company has streamlined operations through various initiatives, resulting in significant reductions in SG&A expenses [7]. Market Position and Valuation - Year-to-date, Carvana's shares have increased by 26%, outperforming competitors like CarMax and Sonic Automotive [8]. - Carvana trades at a forward 12-month P/S ratio of 2.97, significantly higher than CarMax (0.37) and Sonic Automotive (0.15), reflecting stronger growth expectations [11]. Strategic Initiatives - Carvana's turnaround strategy is yielding positive results, with a focus on achieving positive adjusted EBITDA and improved profitability per vehicle [14]. - The acquisition of ADESA's U.S. operations has strengthened Carvana's logistics and vehicle processing capabilities, positioning it for growth in a fragmented market [15]. Future Outlook - Despite economic challenges, Carvana's enhanced efficiency and strong fundamentals suggest a promising growth trajectory, with expectations of an earnings beat in the upcoming quarter [16].
Murphy Oil to Release Q1 Earnings: Here's What You Need to Know
ZACKS· 2025-05-05 12:25
Murphy Oil Corporation (MUR) is scheduled to release first-quarter 2025 results on May 7, after market close. The company delivered a negative earnings surprise of 37.5% in the last reported quarter. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Increased capital investments are expected to have further enhanced the company's offshore operations, since 45% of total investments are targeted toward offshore. Murphy Oil's ongoing debt-reduction initiatives are expected to have lowered ...
Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1
Seeking Alpha· 2025-05-04 14:30
Group 1 - The Q1 earnings season is performing well, with 72% of S&P 500 companies that have reported beating estimates [1] - The blended year-over-year earnings advance is currently at 12.8%, which is five percentage points above the previous level [1]
Assurant Gears Up to Report Q1 Earnings: Here's What to Expect
ZACKS· 2025-05-02 15:10
Assurant, Inc. (AIZ) is expected to register an improvement in its top line but a decline in its bottom line when it reports first-quarter 2025 results on May 6, after the closing bell.The Zacks Consensus Estimate for AIZ’s first-quarter revenues is pegged at $3.05 billion, indicating 5.6% growth from the year-ago reported figure.The consensus estimate for earnings is pegged at $3.00 per share. The Zacks Consensus Estimate for AIZ’s first-quarter earnings has moved up 2.5% in the past 30 days. The estimate ...
Smurfit Westrock is Set to Report Q1 Earnings: Here's What to Expect
ZACKS· 2025-04-29 17:20
Core Viewpoint - Smurfit Westrock PLC is set to report its first-quarter 2025 results on May 1, following the merger of Smurfit Kappa and WestRock in July 2024, with expectations of revenue growth and improved earnings per share [1][2]. Financial Estimates - The Zacks Consensus Estimate for first-quarter revenues is $7.85 billion, reflecting a 4.1% increase from the previous quarter [2]. - The earnings per share estimate is 65 cents, up from 34 cents in the prior quarter, with a 4.8% upward revision in the last 60 days [2]. - Adjusted EBITDA is projected at $1.25 billion for the first quarter of 2025 [4]. Segment Performance - The Europe, MEA, and APAC segment is expected to generate revenues of $2.61 billion, up from $2.52 billion in the fourth quarter, with adjusted EBITDA estimated at $418.6 million [6]. - North America segment revenues are estimated at $4.54 billion, slightly down from $4.59 billion, with adjusted EBITDA expected to rise to $755.3 million [7]. - The LATAM segment is projected to see revenues of $483.6 million, down from $524 million, with adjusted EBITDA estimated at $112.3 million [8]. Market Dynamics - Demand for corrugated packaging and containerboard remains stable, driven by e-commerce growth and the need for sustainable packaging solutions [3]. - However, increased costs related to recovered fiber, labor, and distribution, particularly in Europe, may negatively impact margins [4]. Earnings Prediction - The model indicates a potential earnings beat for Smurfit Westrock, supported by a positive Earnings ESP of +3.72% and a Zacks Rank of 3 [9]. Stock Performance - Smurfit Westrock's shares have decreased by 13.9% over the past six months, compared to a 4.5% decline in the industry [10].
Floor & Decor Q1 Earnings on the Horizon: Key Factors at Play
ZACKS· 2025-04-29 16:20
Core Viewpoint - Floor & Decor Holdings, Inc. is expected to report an increase in revenue for the first quarter of 2025, with a consensus estimate of $1.16 billion, reflecting a 6.1% improvement from the previous year [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for first-quarter earnings per share is stable at 45 cents, indicating a decline of 2.2% from the same period last year [2] - The company has a trailing four-quarter earnings surprise average of 18.2%, with the last reported quarter exceeding estimates by 50% [2] Key Growth Drivers - The company's disciplined expansion strategy, supply chain agility, strategic investments, and merchandise innovation are expected to enhance market share [2] - A persistent supply-demand imbalance in housing and the increasing median age of owner-occupied homes are driving demand for home upgrades and remodeling, benefiting hard surface flooring and related categories [2] Product and Market Expansion - The launch of new product categories, including a semi-custom cabinet program in 40 warehouse stores and online, is anticipated to be a significant revenue catalyst [3] - By entering adjacent remodeling categories such as cabinets and outdoor products, the company is expanding its share of customer projects beyond flooring [3] Store Expansion Strategy - The disciplined approach to expanding the store footprint is a key driver of top-line growth, focusing on warehouse-format store openings in markets with existing brand awareness [4] - The strategic push to capture a larger share of the professional customer base is gaining traction [4] Sales Performance Concerns - A soft start to the first quarter is noted, with comparable store sales declining 1.7% as of February 20, indicating that momentum from the previous quarter may not have continued [5] - The company has diversified its sourcing away from China, reducing reliance from 50% in 2018 to 18% in 2024, although tariffs remain a challenge [5] Earnings Prediction Model - The current model does not predict a definitive earnings beat for Floor & Decor, as it holds a Zacks Rank of 3 and an Earnings ESP of 0.00% [6][7]
McDonald's Set to Report Q1 Earnings: What's in the Offing?
ZACKS· 2025-04-29 14:31
Core Viewpoint - McDonald's Corporation (MCD) is expected to report a decline in first-quarter 2025 earnings and revenues due to weak traffic and economic pressures on low-income consumers [2][4]. Financial Performance Expectations - The Zacks Consensus Estimate for first-quarter EPS has decreased to $2.64, reflecting a 2.2% drop from the previous year's EPS of $2.70 [2]. - Revenue estimates for the quarter are set at $6.08 billion, indicating a 1.4% year-over-year decline [2]. - U.S. revenues are projected to decline by 0.9% to $2,486.3 million, while revenues from International Operated Markets are expected to decrease by 0.7% to $2,927.1 million [3]. Factors Influencing Performance - Weak traffic, particularly in the U.S. and large international markets, is anticipated to negatively impact revenues [2]. - Economic pressures on low-income consumers have suppressed spending, affecting traffic and average check sizes [2]. - Despite the challenges, strong digital adoption, innovative menu offerings, and strategic unit expansion are expected to support performance [4]. Operational Insights - The company is likely to see a 1% increase in U.S. same-store sales and a 0.9% increase in International Operated Markets comps [5]. - Persistent pressure from elevated commodity prices and wages may have negatively impacted the operating margin during the quarter [5]. Earnings Prediction - The model predicts a potential earnings beat for McDonald's, supported by a positive Earnings ESP of +0.06% and a Zacks Rank of 3 (Hold) [6].
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
ZACKS· 2025-04-29 12:55
Core Viewpoint - Vertex Pharmaceuticals is expected to exceed revenue and earnings expectations in its upcoming first-quarter 2025 results, with projected revenues of $2.82 billion and earnings of $4.22 per share [1]. Group 1: Financial Performance - Year-to-date, Vertex's shares have increased by 23.3%, contrasting with a 5.2% decline in the industry [1]. - The Zacks Consensus Estimate for Trikafta/Kaftrio sales is $2.55 billion, while the company's model estimates it at $2.62 billion [3]. Group 2: Product Sales and Pipeline - Sales growth in Vertex's cystic fibrosis (CF) franchise is primarily driven by Trikafta/Kaftrio, particularly in younger demographics [3]. - Higher sales of Trikafta/Kaftrio may have led to a decline in sales of other CF drugs, including Symdeko, Orkambi, and Kalydeco [4]. - Vertex's gene therapy, Casgevy, approved for sickle cell disease and transfusion-dependent beta-thalassemia, generated $8 million in sales in the last quarter, with expectations for higher sales in Q1 2025 [5]. - The FDA approved Vertex's Journavx for moderate-to-severe acute pain in January 2025 [6]. - Alyftrek, a new CFTR modulator therapy, received FDA approval in December 2024 and is under review in the EU, with a positive opinion from the EMA [7]. Group 3: Upcoming Earnings Call Expectations - Investors are looking for updates on the commercial launch of Alyftrek and Journavx, as well as progress on other pipeline candidates targeting various diseases [8]. - Vertex has had a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.58% [9]. Group 4: Earnings Prediction - The model predicts an earnings beat for Vertex, supported by a positive Earnings ESP of +0.40% [10].
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
ZACKS· 2025-04-25 18:30
Core Viewpoint - Investors are keenly awaiting Exelixis' first-quarter 2025 results, particularly focusing on the performance of its lead drug, Cabometyx, with sales and earnings estimates at $502.8 million and 42 cents per share respectively [1] Group 1: Financial Performance - Exelixis has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 26.87%, including a 7.84% beat in the last reported quarter [1] - The Zacks Consensus Estimate for Cabometyx sales is $434 million, while the model estimate is $457.3 million, indicating strong sales performance [3] - Collaboration revenues have increased due to higher royalty revenues from cabozantinib sales outside the U.S., a trend expected to continue [4] Group 2: Product Developments - Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma, maintaining its status as the leading TKI for RCC [3] - Recent FDA approvals expanded Cabometyx's label for treating adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET) [5][6] Group 3: Share Repurchase and Financial Strategy - The board has authorized a $500 million stock repurchase program, expected to commence after completing the ongoing $500 million program [7] - Ongoing share repurchases are likely to positively impact the bottom line, although operating expenses may rise due to costs associated with a broader portfolio [7] Group 4: Earnings Prediction - The earnings model predicts a potential earnings beat for Exelixis, supported by a positive Earnings ESP of +7.14% and a Zacks Rank of 3 [8][9] - The Most Accurate Estimate for earnings is 45 cents per share, compared to the consensus estimate of 42 cents [9] Group 5: Stock Performance - Exelixis shares have gained 11.4% year-to-date, contrasting with a 3.7% decline in the industry [12]
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
ZACKS· 2025-04-23 12:50
Incyte Corporation (INCY) is expected to beat estimates when it reports first-quarter 2025 earnings results on April 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $1.01 billion, while the same for earnings is pinned at $1.05 per share. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.) Let's see how things might have shaped up prior to the announcement. Factors Likely to Influence INCY's Q1 Results Incyte primaril ...